ARI reports Q4 2023 Distributable EPS $0.36; net income per diluted share $0.30

Apollo Commercial Real Estate Finance, Inc.

2023-FY EPS reported $0.29 revenue$344,591,000

Q4 net income available to common stockholders per diluted share $0.30; FY 2023 $0.29.
Q4 Distributable Earnings per share $0.36; FY Distributable Earnings prior to net realized loss/gain $1.69.
CEO Stuart Rothstein notes stable dividend coverage and two new loan originations in Q4.
Realized loss on subordinate loan secured by ultra-luxury residential property and hotel acquired via deed-in-lieu; offset by gain on convertible note extinguishment.
Conference call to discuss results scheduled for February 7, 2024 at 10am ET.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Apollo Commercial Real Estate Finance, Inc. reported the quarter and year ended December 31, 2023 results: EPS $0.30 and $0.29 for the quarter and year ended December 31, 2023, respectively.

Period: the quarter and year ended December 31, 2023
EPS: $0.30 and $0.29 for the quarter and year ended December 31, 2023, respectively
Result: reported results

Exact text from the filing

Apollo Commercial Real Estate Finance, Inc. (the "Company" or "ARI") (NYSE:ARI) today reported results for the quarter and year ended December 31, 2023. Net income available to common stockholders per diluted share of common stock was $0.30 and $0.29 for the quarter and year ended December 31, 2023, respectively.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

Apollo Commercial Real Estate Finance, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-025589

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.